Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer [Phase 3]

View source ↗

Summary

A phase 3 clinical trial is evaluating IBI310 in combination with sintilimab as neoadjuvant therapy for resectable MSI-H/dMMR colon cancer; recruitment is ongoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Msi-h Dmmr Colorectal Cancer

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: MSI-H | Phase 3 | Status: RECRUITING